Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed epithelial carcinoma arising in the ovary, fallopian tube,
or peritoneum

- Any stage and grade at diagnosis

- Must have received initial cytoreductive surgery and chemotherapy with ≥ 1
platinum-based chemotherapy regimen

- Persistent or recurrent disease after initial therapy

- In complete clinical remission after chemotherapy for recurrent disease, meeting all
of the following criteria:

- CA125 ≤ 35 units/L

- Normal physical examination

- No definite evidence of disease by CT scan of the abdomen and pelvis

- Lymph nodes and/or soft tissue abnormalities ≤ 1.0 cm are not considered
definite evidence of disease

- No known brain metastases

PATIENT CHARACTERISTICS:

Inclusion criteria:

- Karnofsky performance status 70-100%

- Life expectancy > 3 months

- ANC ≥ 1,500/mm³

- Platelet count ≥ 100,000/mm³

- Hemoglobin ≥ 9.0 g/dL

- INR < 1.5 OR PT/PTT within normal limits

- Creatinine ≤ 1.5 times upper limit of normal (ULN)

- Urinalysis negative for protein

- If urinalysis shows 1+ protein by dipstick or protein ≥ 30-100 mg/dL by
semi-quantitative assay, a 24-hour urine collection is required

- Eligible patients must have a total urinary protein ≤ 500 mg AND measured
creatinine clearance ≥ 50 mL/min from a 24-hour urine collection

- Bilirubin ≤ 1.5 times ULN

- AST and ALT ≤ 2.5 times ULN

- Alkaline phosphatase ≤ 2.5 times ULN

- Stable blood pressure (BP) measurement required on 3 separate days prior to the start
of treatment

- No peripheral neuropathy > grade 1

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

Exclusion criteria:

- Other invasive malignancies within the past 5 years, except nonmelanoma skin cancer

- Uncontrolled concurrent illness or medical condition including, but not limited to,
any of the following:

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia

- Uncontrolled diabetes

- Psychiatric illness or social situation that would preclude study compliance

- Uncontrolled hypertension defined as a persistent BP > 150/100 mm Hg (or a persistent
BP > 180/90 mm Hg if the patient has a history of isolated systolic hypertension)
despite ≥ 2 attempts at antihypertensive medication dosage adjustment ≥ 2 weeks apart

- Thrombolic or embolic events such as cerebrovascular accident, including transient
ischemic attack, within the past 6 months

- Pulmonary hemorrhage or bleeding event ≥ grade 2 within 4 weeks of the first dose of
study drug

- Other hemorrhage or bleeding event ≥ grade 3 within 4 weeks of the first dose of
study drug

- Serious nonhealing wound, ulcer, or bone fracture

- Evidence or history of bleeding diathesis or coagulopathy

- Inability to take oral medications or gastrointestinal condition that compromises
absorption

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to sorafenib tosylate

PRIOR CONCURRENT THERAPY:

Inclusion criteria:

- See Disease Characteristics

- No prior sorafenib tosylate or other inhibitors of MAPK signaling intermediates or
angiogenesis inhibitors

- No prior cancer treatment that would contraindicate protocol therapy

- More than 4 weeks since prior radiotherapy

- More than 3 weeks since prior chemotherapy, biological therapy, or immunotherapy

- More than 1 week since prior hormonal therapy for cancer treatment

Exclusion criteria:

- Major surgery (i.e., laparotomy) within the past 4 weeks or minor surgery within the
past 2 weeks

- Placement of a vascular access device is not considered minor surgery

- Concurrent combination antiretroviral therapy for HIV-positive patients

- Concurrent St. John wort, rifampin, or enzyme-inducing anticonvulsants (e.g.,
carbamazepine, phenytoin, or phenobarbital)